Laboratory Medicine Program

CA19-9

Clinical Decription:
Measurements of carbohydrate antigen 19-9 (CA 19-9) in human serum and plasma are used in conjunction with other procedures to aid in the diagnosis, prognosis and management of pancreatic and other gastrointestinal cancers. Elevated concentrations are associated with malignant diseases, such as pancreatic, colorectal, gastric, hepatocellular and hepatobiliary cancers, as well as benign diseases, such as acute and chronic pancreatitis, liver cirrhosis, cholangitis and obstructive jaundice. Elevated concentrations are associated with malignant diseases, such as pancreatic, colorectal, gastric, hepatocellular and hepatobiliary cancers, as well as benign diseases, such as acute and chronic pancreatitis, liver cirrhosis, cholangitis and obstructive jaundice. CA 19-9 is not useful for screening malignancies in asymptomatic individuals but can be valuable in diagnosing and monitoring pancreatic and hepatobiliary cancer. It may also be emerging as a marker for post-operative disease monitoring in colorectal cancer, in conjunction with carcinoembryonic antigen (CEA).

Method: ECLIA; Roche Cobas e402

Component Tests Used: n/a

Reference Ranges Used:
<35 kU/L

Specimen Type: Serum
Volume: 2 mL (minimum: 2 mL)

Shipping: Room temperature

Special Instructions: Serum Stability: 5 days at 20 - 25°C, 14 days at 2 - 8°C

Testing Schedule(s): Monday through Friday.

Turnaround Time: 3 days

For more information, call 416.340.5227 or 1.866.865.5227